Literature DB >> 23787074

Consideration of tumor size improves the accuracy of TNM predictions in patients with gastric cancer after curative gastrectomy.

Jun Lu1, Chang-ming Huang, Chao-hui Zheng, Ping Li, Jian-wei Xie, Jia-Bin Wang, Jian-xian Lin.   

Abstract

OBJECTIVE: To investigate whether addition of tumor size improves the prognostic accuracy of the UICC 7th TNM staging system in gastric cancer patients who underwent radical surgery (R0 resection).
METHODS: The clinical and pathological data and postoperative 5-year survival rate of 507 patients with gastric cancer who underwent radical surgery (R0 resection) in our department from January 2004 to June 2006 were evaluated retrospectively. The prognostic accuracy of conventional UICC 7th TNM staging was compared with that of UICC 7th TNM staging plus tumor size. The ability of tumor size to improve the 95% confidence interval (CI) of postoperative 5-year survival rate in gastric cancer patients was assessed.
RESULTS: Of the 507 patients, 470 (92.7%) were followed up. The five-year survival rate of these patients was 50.4%. The survival rates of patients with pT1, pT2, pT3, and pT4 stage tumors were 89.3%, 72.4%, 36.9%, and 23.7%, respectively (P < 0.05), and the survival rates of patients with pN0, pN1, pN2, and pN3 stage tumors were 75.2%, 68.8%, 46.7%, and 21.3% (P < 0.05). Depth of invasion, lymph node metastasis stage, metastatic lymph node ratio (MLR), lymphatic invasion and tumor size were independent predictors of patient prognosis. The accuracy of UICC 7th TNM staging in predicting 5-year survival was 75.4% and the accuracy of tumor size plus the UICC 7th TNM staging was 77.9% (P < 0.05). This combination improved the 95% CI of postoperative 5-year survival rate in gastric cancer patients.
CONCLUSION: Tumor size can improve the accuracy of UICC 7th TNM staging in predicting survival in gastric cancer patients following radical surgery (R0 resection). Tumor size is likely to be another important indicator in future UICC-TNM staging systems for gastric cancer patients. Crown
Copyright © 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gastric cancer; Predication; Prognosis; TNM; Tumor size

Mesh:

Year:  2013        PMID: 23787074     DOI: 10.1016/j.suronc.2013.05.002

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  26 in total

1.  Evaluating TNM stage prognostic ability in a population-based cohort of gastric adenocarcinoma patients in a low-incidence country.

Authors:  Alyson L Mahar; Brandon Zagorski; Daniel Kagedan; Matthew Dixon; Abraham El-Sedfy; Jovanka Vasilevska-Ristovska; Daniela Cortinovis; Corwyn Rowsell; Calvin Law; Lucy Helyer; Lawrence Paszat; Natalie Coburn
Journal:  Can J Public Health       Date:  2018-08-08

2.  CT volumetry can potentially predict the local stage for gastric cancer after chemotherapy.

Authors:  Zhi Cong Wang; Chen Wang; Ying Ding; Yuan Ji; Meng Su Zeng; Sheng Xiang Rao
Journal:  Diagn Interv Radiol       Date:  2017 Jul-Aug       Impact factor: 2.630

Review 3.  Noninvasive detection of gastric cancer.

Authors:  Qin-Si Wan; Kun-He Zhang
Journal:  Tumour Biol       Date:  2016-07-06

4.  lncRNA-AC130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis.

Authors:  Chunjing Xu; Yongfu Shao; Tian Xia; Yunben Yang; Jiawei Dai; Lin Luo; Xinjun Zhang; Weiliang Sun; Haojun Song; Bingxiu Xiao; Junming Guo
Journal:  Tumour Biol       Date:  2014-06-27

5.  High expression of CD11c indicates favorable prognosis in patients with gastric cancer.

Authors:  Yuan Wang; Bin Xu; Wen-Wei Hu; Lu-Jun Chen; Chang-Ping Wu; Bin-Feng Lu; Yue-Ping Shen; Jing-Ting Jiang
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

6.  Analysis of lymph node metastasis correlation with prognosis in patients with T2 gastric cancer.

Authors:  Xiaowen Liu; Ziwen Long; Hong Cai; Hua Huang; Yingqiang Shi; Yanong Wang
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

7.  Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study.

Authors:  Xuefeng Yu; Fulan Hu; Qiang Yao; Chunfeng Li; Hongfeng Zhang; Yingwei Xue
Journal:  BMC Cancer       Date:  2016-07-14       Impact factor: 4.430

8.  A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.

Authors:  Jing Qian; Yingying Qian; Jian Wang; Bing Gu; Dong Pei; Shaohua He; Fang Zhu; Oluf Dimitri Røe; Jin Xu; Lianke Liu; Yanhong Gu; Renhua Guo; Yongmei Yin; Yongqian Shu; Xiaofeng Chen
Journal:  Drug Des Devel Ther       Date:  2016-02-24       Impact factor: 4.162

9.  LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition.

Authors:  Yuehua Han; Jun Ye; Dang Wu; Pin Wu; Zhigang Chen; Jian Chen; Shunliang Gao; Jian Huang
Journal:  BMC Cancer       Date:  2014-12-11       Impact factor: 4.430

10.  Prognostic Significance of Tumor Size in 2405 Patients With Gastric Cancer: A Retrospective Cohort Study.

Authors:  Lin-Yong Zhao; Wei-Han Zhang; Xin-Zu Chen; Kun Yang; Xiao-Long Chen; Kai Liu; Bo Zhang; Zhi-Xin Chen; Jia-Ping Chen; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.